Orchestra BioMed Holdings, Inc. 8-K

What Happened
Orchestra BioMed Holdings, Inc. (OBIO) filed an 8‑K (Item 8.01) on January 12, 2026, announcing it expects to receive up to $21 million in proceeds related to the acquisition of Vivasure by Haemonetics. The company issued a press release on the same date (attached as Exhibit 99.1) describing the transaction and the expected cash consideration.

Key Details

• The 8‑K was filed on January 12, 2026 and incorporates a press release dated January 12, 2026 (Exhibit 99.1).
• Orchestra says it will receive up to $21 million in proceeds tied to Haemonetics’ acquisition of Vivasure.
• The disclosure was made under Item 8.01 (Other Events) of Form 8‑K.

Why It Matters
This disclosure notifies investors that Orchestra may receive a material cash payment (up to $21M) from the Vivasure acquisition, which could affect the company’s liquidity and funding for its operations or programs. Investors should watch for future filings or company updates clarifying the timing, certainty, and form of the proceeds.